• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.供者特征对血液系统恶性肿瘤异基因供者移植后生存的影响。
Blood. 2016 Jan 14;127(2):260-7. doi: 10.1182/blood-2015-08-663823. Epub 2015 Nov 2.
2
Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation.单抗原不匹配与匹配的无关供者造血细胞移植后的可比结局。
J Cancer Res Clin Oncol. 2015 Dec;141(12):2193-203. doi: 10.1007/s00432-015-2003-5. Epub 2015 Jul 1.
3
Donor selection in a pediatric stem cell transplantation cohort using PIRCHE and HLA-DPB1 typing.采用 PIRCHE 和 HLA-DPB1 分型对儿科干细胞移植队列进行供者选择。
Pediatr Blood Cancer. 2020 Mar;67(3):e28127. doi: 10.1002/pbc.28127. Epub 2019 Dec 18.
4
Donor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies.非血缘供者移植中,降低强度预处理方案对血液恶性肿瘤患者移植物失败、移植物抗宿主病和生存的影响因素分析。
Biol Blood Marrow Transplant. 2011 Dec;17(12):1869-73. doi: 10.1016/j.bbmt.2011.07.008. Epub 2011 Jul 20.
5
Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.KIR基因型的供受者匹配可减少慢性移植物抗宿主病,且缺乏抑制性KIR配体可预防清髓性、HLA匹配的造血细胞移植后的复发。
PLoS One. 2016 Jun 24;11(6):e0158242. doi: 10.1371/journal.pone.0158242. eCollection 2016.
6
Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation.在无关供者造血细胞移植中定位 MHC 单倍型效应。
Blood. 2013 Mar 7;121(10):1896-905. doi: 10.1182/blood-2012-11-465161. Epub 2013 Jan 10.
7
Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era.近年来非亲缘供者造血细胞移植后的生存率有显著提高。
Biol Blood Marrow Transplant. 2015 Jan;21(1):142-50. doi: 10.1016/j.bbmt.2014.10.001. Epub 2014 Oct 15.
8
Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts.与匹配的无关供者移植相比,单抗原错配的无关供者或高度人类白细胞抗原不相合的单倍体相合家庭供者骨髓移植治疗血液系统恶性肿瘤具有更高的生存率:为替代供者移植受者建立治疗算法。
Blood. 2002 Feb 1;99(3):806-14. doi: 10.1182/blood.v99.3.806.
9
Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.供体类型和预处理方案强度对镰状细胞病患者异基因移植结局的影响:一项回顾性多中心队列研究
Lancet Haematol. 2019 Nov;6(11):e585-e596. doi: 10.1016/S2352-3026(19)30154-1. Epub 2019 Sep 5.
10
High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis.高分辨率 HLA 配型在造血干细胞移植中的应用:一项回顾性协作分析。
Blood. 2013 Oct 31;122(18):3220-9. doi: 10.1182/blood-2013-02-482547. Epub 2013 Sep 17.

引用本文的文献

1
Aging-related, senescence-associated secretory phenotype and allogeneic hematopoietic cell transplantation outcomes in older patients.老年患者中与衰老相关的、衰老相关分泌表型及异基因造血细胞移植结局
J Geriatr Oncol. 2025 Aug 19;16(8):102346. doi: 10.1016/j.jgo.2025.102346.
2
Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings.与年长的同胞相比,年轻的非亲属供者为髓系恶性肿瘤患者带来生存优势。
Leukemia. 2025 Aug 6. doi: 10.1038/s41375-025-02724-1.
3
In search of the perfect donor: youth must be served.寻找完美供体:必须关注年轻人。
Blood Adv. 2025 Jul 22;9(14):3540-3542. doi: 10.1182/bloodadvances.2025016207.
4
Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR.异基因造血细胞供体选择:来自NMDP/CIBMTR的当代指南
Transplant Cell Ther. 2025 Jul 5. doi: 10.1016/j.jtct.2025.07.004.
5
Understanding Telomere Biology in Hematopoietic Cell Transplantation: A Dynamical Systems Perspective.从动态系统角度理解造血细胞移植中的端粒生物学
Transplant Cell Ther. 2025 Jul 1. doi: 10.1016/j.jtct.2025.06.024.
6
Characterisation of the ABO Blood Group Phenotypes Using Third-Generation Sequencing.使用第三代测序技术对ABO血型表型进行表征
Int J Mol Sci. 2025 Jun 6;26(12):5443. doi: 10.3390/ijms26125443.
7
Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis.单倍体相合与不匹配无关供者造血干细胞移植并采用移植后环磷酰胺预防的结果
Blood Adv. 2025 Aug 12;9(15):4023-4036. doi: 10.1182/bloodadvances.2025016236.
8
Graft Source Choice.移植物来源的选择。
Adv Exp Med Biol. 2025;1475:57-75. doi: 10.1007/978-3-031-84988-6_4.
9
Impact of HLA locus mismatch on peripheral blood allogeneic hematopoietic stem cell transplantation from unrelated donors using an ATG-based GVHD prophylaxis strategy.使用基于抗胸腺细胞球蛋白的移植物抗宿主病预防策略时,HLA位点错配对无关供者外周血异基因造血干细胞移植的影响。
Blood Res. 2025 Jun 3;60(1):34. doi: 10.1007/s44313-025-00082-6.
10
Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations.在HLA不匹配的无关供体和单倍型相合供体之间进行选择:供体年龄的考量
Transplant Cell Ther. 2025 Sep;31(9):680-692. doi: 10.1016/j.jtct.2025.05.019. Epub 2025 May 24.

本文引用的文献

1
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.单倍体相合移植联合移植后环磷酰胺与匹配无关供者移植治疗急性髓系白血病
Blood. 2015 Aug 20;126(8):1033-40. doi: 10.1182/blood-2015-04-639831. Epub 2015 Jun 30.
2
Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation.非允许性HLA - DPB1错配会增加清髓性非亲缘异基因造血细胞移植后的死亡率。
Blood. 2014 Oct 16;124(16):2596-606. doi: 10.1182/blood-2014-05-576041. Epub 2014 Aug 26.
3
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.美国注册中心造血干细胞移植供者 HLA 配型概率。
N Engl J Med. 2014 Jul 24;371(4):339-48. doi: 10.1056/NEJMsa1311707.
4
Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation.供者巨细胞病毒状态影响异基因造血干细胞移植的结局:欧洲血液和骨髓移植组的研究。
Clin Infect Dis. 2014 Aug 15;59(4):473-81. doi: 10.1093/cid/ciu364. Epub 2014 May 20.
5
High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis.高分辨率 HLA 配型在造血干细胞移植中的应用:一项回顾性协作分析。
Blood. 2013 Oct 31;122(18):3220-9. doi: 10.1182/blood-2013-02-482547. Epub 2013 Sep 17.
6
A perspective on the selection of unrelated donors and cord blood units for transplantation.移植中无关供者和脐带血单位选择的观点。
Blood. 2012 Jul 12;120(2):259-65. doi: 10.1182/blood-2012-03-379032. Epub 2012 May 17.
7
The EBMT risk score.欧洲血液与骨髓移植学会风险评分
Bone Marrow Transplant. 2012 Jun;47(6):749-56. doi: 10.1038/bmt.2011.110. Epub 2011 Jun 6.
8
Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.非血缘供者移植后经减低强度预处理:使用部分 HLA 错配相关骨髓或无关双脐血移植物的平行 2 期试验结果。
Blood. 2011 Jul 14;118(2):282-8. doi: 10.1182/blood-2011-03-344853. Epub 2011 Apr 28.
9
HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.HLA-C 抗原错配与无关供体外周血造血干细胞移植后不良结局相关。
Biol Blood Marrow Transplant. 2011 Jun;17(6):885-92. doi: 10.1016/j.bbmt.2010.09.012. Epub 2010 Sep 24.
10
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis.移植物来源对成人急性白血病异基因造血干细胞移植的影响:一项回顾性分析。
Lancet Oncol. 2010 Jul;11(7):653-60. doi: 10.1016/S1470-2045(10)70127-3.

供者特征对血液系统恶性肿瘤异基因供者移植后生存的影响。

The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.

机构信息

Jaeb Center for Health Research, Tampa, FL;

Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, MN;

出版信息

Blood. 2016 Jan 14;127(2):260-7. doi: 10.1182/blood-2015-08-663823. Epub 2015 Nov 2.

DOI:10.1182/blood-2015-08-663823
PMID:26527675
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4713163/
Abstract

There are >24 million registered adult donors, and the numbers of unrelated donor transplantations are increasing. The optimal strategy for prioritizing among comparably HLA-matched potential donors has not been established. Therefore, the objective of the current analyses was to study the association between donor characteristics (age, sex, parity, cytomegalovirus serostatus, HLA match, and blood group ABO match) and survival after transplantation for hematologic malignancy. The association of donor characteristics with transplantation outcomes was examined using either logistic or Cox regression models, adjusting for patient disease and transplantation characteristics associated with outcomes in 2 independent datasets: 1988 to 2006 (N = 6349; training cohort) and 2007 to 2011 (N = 4690; validation cohort). All donor-recipient pairs had allele-level HLA typing at HLA-A, -B, -C, and -DRB1, which is the current standard for selecting donors. Adjusting for patient disease and transplantation characteristics, survival was better after transplantation of grafts from young donors (aged 18-32 years) who were HLA matched to recipients (P < .001). These findings were validated for transplantations that occurred between 2007 and 2011. For every 10-year increment in donor age, there is a 5.5% increase in the hazard ratio for overall mortality. Increasing HLA disparity was also associated with worsening survival. Donor age and donor-recipient HLA match are important when selecting adult unrelated donors. Other donor characteristics such as sex, parity, and cytomegalovirus serostatus were not associated with survival. The effect of ABO matching on survival is modest and must be studied further before definitive recommendations can be offered.

摘要

有超过 2400 万注册的成年供体,非亲属供体移植的数量正在增加。尚未确定在可比 HLA 匹配的潜在供体中进行优先排序的最佳策略。因此,目前分析的目的是研究供体特征(年龄、性别、产次、巨细胞病毒血清状态、HLA 匹配和血型 ABO 匹配)与血液恶性肿瘤移植后生存的关系。使用逻辑或 Cox 回归模型检查供体特征与移植结果的关系,调整与患者疾病和移植结果相关的特征,这些特征在 2 个独立数据集(1988 年至 2006 年,N=6349;训练队列;2007 年至 2011 年,N=4690;验证队列)中与结果相关。所有供受者对均进行 HLA-A、-B、-C 和-DRB1 等位基因水平 HLA 分型,这是选择供体的当前标准。调整患者疾病和移植特征后,与 HLA 匹配的年轻供体(年龄 18-32 岁)移植后的存活率更好(P<0.001)。这些发现已在 2007 年至 2011 年期间进行的移植中得到验证。供体年龄每增加 10 岁,总死亡率的危险比增加 5.5%。HLA 差异增加也与生存恶化相关。在选择成年非亲属供体时,供体年龄和供受者 HLA 匹配是重要的。其他供体特征,如性别、产次和巨细胞病毒血清状态与生存无关。ABO 匹配对生存的影响是适度的,在提出明确建议之前还需要进一步研究。